Nasdaq: Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission
Nasdaq: Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile
Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile
Google has published a new help document on the topic of Google Business Profile negative review extortion scams. The document explains what they are, how to report the scam, what to expect and more ...
The Global Risks Report 2026 analyses global risks through three timeframes to support decision-makers in balancing current crises and longer-term priorities.
The Global Risks Report 2025 analyses global risks to support decision-makers in balancing current crises and longer-term priorities.
When the Future of Jobs Report was first published in 2016, surveyed employers expected that 35% of workers’ skills would face disruption in the coming years. The COVID-19 pandemic, along with rapid advancements in frontier technologies, led to significant disruptions in working life and skills, prompting respondents to predict high levels of skills instability in subsequent editions of the ...
Geoeconomic confrontation, interstate conflict and extreme weather emerge as top risks for the year, says World Economic Forum Global Risks Report 2026.
Global Risks Report 2026: Geopolitical and Economic Risks Rise in New ...
The Forum’s Future of Jobs Report 2025 examines how broadening digital access is affecting the world of work – and looks at the fastest growing and declining job roles.
Future of Jobs Report 2025: These are the fastest growing and declining ...
Future of Jobs Report 2025: 78 Million New Job Opportunities by 2030 ...
Technological change, geoeconomic fragmentation, economic uncertainty, demographic shifts and the green transition – individually and in combination are among the major drivers expected to shape and transform the global labour market by 2030. The Future of Jobs Report 2025 brings together the perspective of over 1,000 leading global employers—collectively representing more than 14 million ...
These are the jobs predicted to see the highest growth in demand and the skills workers will likely need, according to the Future of Jobs Report 2025.
Future of Jobs Report 2025: The jobs of the future - The World Economic ...
The World Economic Forum's Global Cybersecurity Outlook 2026, written in collaboration with Accenture, examines the cybersecurity trends that will affect economies and societies in the year to come. The report explores how accelerating AI adoption, geopolitical fragmentation and widening cyber inequity are reshaping the global risk landscape. As attacks grow faster, more complex and more ...
Progress towards the UN's Sustainable Development Goals is slow, with only 18% on track for 2030, according to the UN’s latest update report.
The World Economic Forum’s latest Top 10 Emerging Technologies report explores the tech on the cusp of making a massive impact on our lives.
siliconera: Square Enix Cissnei FFVII Rebirth Profile Explains What She’s Been Doing
Bimekizumab demonstrated a consistent safety profile across patients with PsA or axSpA in an integrated safety analysis, with the drug showing long-term tolerability.
Yahoo Finance: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Absence of neurotoxicity of any grade in low-volume disease to-date highlights a significant safety profile for NXC-201, which is crucial for patient acceptance and regulatory approval. Company is on ...
The 5-year “real-world” safety profile of esketamine nasal spray for depression was consistent with prior clinical trial data, with most adverse events (AEs) being transient and serious AEs observed ...
Nemvaleukin showed promising antitumor activity and manageable safety in advanced solid tumors, both alone and with pembrolizumab. ARTISTRY-1 study included dose-escalation, dose-expansion, and ...
MADRID — Real-world data on tirzepatide (Eli Lilly and Company) from a large population database suggest a safety profile of the drug consistent with that in clinical trials and similar to that of ...
World Socialist Web Site: Massive study confirms safety profile of COVID-19 vaccines
A study on 93 million individuals worldwide who received one of the major COVID-19 vaccines confirmed existing knowledge about the safety profile of these vaccines. Adverse events of special interest ...
The American Journal of Managed Care: Zanubrutinib's Safety Profile in CLL Reinforced in 5-Year Follow-Up of SEQUOIA
The SEQUOIA study's 5-year follow-up confirms zanubrutinib's safety profile and low cardiovascular events in treatment-naive chronic lymphocytic leukemia, according to Mazyar Shadman, MD, MPH, of Fred ...
ascopubs.org: Comparative safety profiles of lutetium-177 and enzalutamide: A pharmacovigilance study and disproportionality analysis using real world data.
Comparative safety profiles of lutetium-177 and enzalutamide: A pharmacovigilance study and disproportionality analysis using real world data.
Seeking Alpha: Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
PharmiWeb: ICOTYDE™ (icotrokinra) one-year results demonstrate lasting skin clearance and favourable safety profile in once-daily tablet for plaque psoriasis
ICOTYDE™ (icotrokinra) one-year results demonstrate lasting skin clearance and favourable safety profile in once-daily tablet for plaque psoriasis
Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
We’ve gone over the basics of CAN and looked into how CAN databases work. Now we will look at a few protocols that are commonly used over CAN. In the last article we looked at CAN databases, where ...
The New England Journal of Medicine: Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Search Engine Roundtable: New: Google Business Profile Report Negative Review Extortion Scams